Nishanth Thalambedu

Assistant Professor

UAMS

Also affiliated: Thomas Jefferson University (2020); Thomas Jefferson University Hospital (2019–2023); Abington Memorial Hospital (2019–2022); Jefferson University Hospitals (2021); Winrock International (United States) (2026); Winthrop Rockefeller Foundation (2022–2023); Jefferson Hospital (2019–2023); Arkansas Department of Agriculture (2024)

Faculty Researcher

Internal Medicine, College of Medicine

8 h-index 66 pubs 253 cited

Research Areas

Biomedical Subjects

Links

Research Group UAMS TRI Profile

OverviewAI-generated summary

Nishanth Thalambedu's research focuses on the clinical outcomes and treatment of multiple myeloma, a type of blood cancer. He has investigated the feasibility of outpatient stem cell transplantation for these patients and identified risk factors predictive of hospital admission. His work also examines the effectiveness of CAR-T cell therapy, specifically BCMA-directed therapies, in patients with relapsed or refractory multiple myeloma. Additionally, Thalambedu has explored the role of vertebral augmentation procedures in managing multiple myeloma and studied trends and outcomes in aortic valve replacement surgeries, including transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) in both cancer and non-cancer patients. He has also contributed to understanding corneal toxicity associated with certain cancer treatments like belantamab mafodotin.

Metrics

h-index: 8
Publications: 66
Citations: 253

Selected Publications

Real-world analysis of CRS and ICANS following tarlatamab and its association with survival in patients with SCLC. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Impact of the CAR-T era on survival in diffuse large B-cell lymphoma: A u.S. population-based cohort study (2025)

Blood DOI OpenAlex
Editorial: Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology (2025)

Frontiers in Medicine DOI OpenAlex
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)

Diagnostics 6 citations DOI OpenAlex
Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: opportunities, challenges, and future directions (2025)

Frontiers in Medicine 12 citations DOI OpenAlex
Role of proliferation-related genes as predictive factors for adjuvant therapy in colon cancer. (2025)

Journal of Clinical Oncology DOI OpenAlex
Abstract 1124: Mining the Kras-p53 mutational interface for synthetic lethality (SL) in pancreatic adenocarcinoma (PA) (2025)

Cancer Research DOI OpenAlex
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)

Cancers 5 citations DOI OpenAlex
Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case (2024)

Annals of Internal Medicine Clinical Cases DOI OpenAlex
Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database (2024)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
HL-697 Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database (2024)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Abstract B009: Exploring the putative Kras-p53 mutational interface for vulnerability (2024)

Molecular Cancer Therapeutics DOI OpenAlex
Demographics and survival outcomes of stage IV male breast cancer: A retrospective analysis of SEER database. (2024)

Journal of Clinical Oncology DOI OpenAlex
CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients (2024)

Journal of the National Comprehensive Cancer Network DOI OpenAlex